A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
A2 Biotherapeutics Inc.
Seagen Inc.
Novartis
Var2 Pharmaceuticals
A2 Biotherapeutics Inc.
Elicio Therapeutics
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Shanghai Cingularbio Co. Ltd
Tempus AI
Revolution Medicines, Inc.
Chongqing Precision Biotech Co., Ltd
UTC Therapeutics Inc.
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Klus Pharma Inc.
Novartis
MacroGenics
SpeciCare
SPGO Research Mannheim GmbH
INSYS Therapeutics Inc
Siemens Molecular Imaging